Quince Therapeutics Enters Material Definitive Agreement
Ticker: QNCX · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Quince Therapeutics just signed a big deal, but we don't know what it is yet.
AI Summary
On September 25, 2025, Quince Therapeutics, Inc. entered into a material definitive agreement. This agreement also creates a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. Specific details of the agreement and the financial obligations were not disclosed in this filing.
Why It Matters
This filing indicates Quince Therapeutics has entered into a significant agreement that will likely have financial implications, though the specifics are not yet public.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and financial obligation, but lacks specific details, creating uncertainty.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Registrant
- September 25, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Quince Therapeutics?
The filing does not specify the nature of the material definitive agreement.
What are the specific financial obligations created by this agreement?
The filing states that a direct financial obligation or an obligation under an off-balance sheet arrangement has been created, but does not provide specific details.
When was the earliest event reported in this filing?
The earliest event reported was on September 25, 2025.
What is Quince Therapeutics' principal executive office address?
Quince Therapeutics' principal executive office is located at 601 Gateway Boulevard, Suite 1250, South San Francisco, California 94080.
What is Quince Therapeutics' IRS Employer Identification No.?
Quince Therapeutics' IRS Employer Identification No. is 90-1024039.
Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-26 16:45:23
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share QNCX The Nasdaq Stock Mar
Filing Documents
- d911581d8k.htm (8-K) — 24KB
- 0001193125-25-220722.txt ( ) — 136KB
- qncx-20250925.xsd (EX-101.SCH) — 3KB
- qncx-20250925_lab.xml (EX-101.LAB) — 18KB
- qncx-20250925_pre.xml (EX-101.PRE) — 11KB
- d911581d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUINCE THERAPEUTICS, INC. Date: September 26, 2025 By: /s/ Dirk Thye Name: Dirk Thye Title: Chief Executive Officer and Chief Medical Officer